What is the current Parkinson's Disease Therapeutics market size?

The current market size is approximately USD 4.5 billion as of 2022, growing steadily.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 7.2% from 2023 to 2028, driven by increasing prevalence.

What are the key drivers of the Parkinson's Disease Therapeutics market?

Key drivers include rising disease prevalence, increasing geriatric population, and advancements in treatment options.

What are the major challenges faced by the Parkinson's Disease Therapeutics market?

Challenges include high treatment costs, limited awareness, and lack of curative therapies available currently.

Which regions are leading the Parkinson's Disease Therapeutics market?

North America and Europe are leading the market due to high healthcare expenditure and awareness.

Who are the top companies in the Parkinson's Disease Therapeutics market?

Top companies include Pfizer, GlaxoSmithKline, and Merck, offering a range of therapeutic products.

What future opportunities can be expected in the Parkinson's Disease Therapeutics market?

Future opportunities include emerging therapies, increasing demand for personalized medicine, and growing investments.

How will technology impact the Parkinson's Disease Therapeutics market?

Technology will drive the market through innovative diagnostic tools, wearables, and digital therapeutics, improving treatment outcomes.

What is the current regulatory landscape of the Parkinson's Disease Therapeutics market?

The regulatory landscape is governed by stringent FDA and EMA guidelines, ensuring safety and efficacy of therapeutic products.

What is the future outlook of the Parkinson's Disease Therapeutics market?

The future outlook is promising, with increasing focus on research and development, and growing demand for effective treatments.

Parkinson's Disease Therapeutics Growth Trends & Opportunity Analysis 2033

Parkinson's Disease Therapeutics by Application (Under 40 Years Old, 40-65 Years Old, Above 65 Years Old), by Types (Sinemet-CR, Trastal, Madopar, COMT Inhibitor, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Parkinson's Disease Therapeutics Market Overview

The Parkinson's Disease Therapeutics market refers to the global marketplace for treatments and therapies aimed at managing and alleviating the symptoms of Parkinson's disease, a neurodegenerative disorder. As the growth outlook for this market continues to evolve, driven by advancements in medical research and an increasing patient population, the Parkinson's Disease Therapeutics market size is expected to reach $8.4 billion by 2026. The market forecast suggests a compound annual growth rate (CAGR) of 9.5% from 2026 to 2033, fueled by macro drivers such as an aging population, rising healthcare expenditure, and ongoing industry expansion. The scope of this market encompasses a range of therapeutic approaches, including pharmacological, surgical, and alternative treatments, catering to the diverse needs of patients worldwide.

Loading chart…

Key forces shaping the Parkinson's Disease Therapeutics industry include technology shifts towards personalized medicine, regulations governing drug development and approval, and changing consumer behavior driven by increased awareness and patient advocacy. The largest region in this market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rising healthcare infrastructure and economic growth. As the market continues to evolve, driven by these forces and macro drivers, strategic planners and business development teams must stay informed about the latest trends and developments to capitalize on emerging opportunities and stay ahead of the competition in the Parkinson's Disease Therapeutics market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Akorn; GSK; Novartis; Boehringer Ingelheim; Teva Pharmaceutical; Abbvie; Kyowa Hakko Kirin Pharma; Astellas Pharma; Roche; H.Lundbeck; Bausch Health; Apokyn; Orion; Stada Arzneimittel; US WorldMeds; Desitin Arzneimittel; Endo Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Parkinson's Disease Therapeutics market is poised for significant growth, driven by factors such as an increasing prevalence of Parkinson's disease, advancements in treatment options, and rising awareness about the condition. The Parkinson's Disease Therapeutics market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in neuroprotection and gene therapy are driving innovation in the Parkinson's Disease Therapeutics market, offering new avenues for treatment and management of the condition.

Government initiatives and funding for research and development in neurodegenerative diseases are fueling the growth of the Parkinson's Disease Therapeutics market, enabling the discovery of novel therapeutics.

Restraints2 items

The high cost of research and development in the Parkinson's Disease Therapeutics market, coupled with the risk of failed trials, is a significant restraint to market growth.

Stringent regulatory requirements and the need for extensive clinical trials are barriers to entry for new players in the Parkinson's Disease Therapeutics market, limiting the pace of innovation.

Opportunities2 items

The increasing demand for personalized medicine and targeted therapies presents opportunities for growth in the Parkinson's Disease Therapeutics market, as patients seek more effective treatment options.

Partnerships and collaborations between biotechnology companies and pharmaceutical firms can accelerate the development of novel therapeutics, driving growth in the Parkinson's Disease Therapeutics market.

Challenges2 items

The complexity of Parkinson's disease and the lack of a cure pose significant challenges to the development of effective therapeutics, requiring ongoing investment in research and development.

The patent cliff for existing therapeutics in the Parkinson's Disease Therapeutics market is a challenge, as companies must balance the need to protect intellectual property with the need to develop new treatments.

Market Segmentation

Loading chart…

The Application segment of the Parkinson's Disease Therapeutics market refers to the various uses of therapeutic treatments for Parkinson's disease. This segment is crucial in understanding the Parkinson's Disease Therapeutics segmentation and its impact on the overall market size. The application segment is further divided into subtypes, including early-stage treatment, late-stage treatment, and symptomatic treatment. Each subtype contributes to the overall market size, with early-stage treatment being the most significant contributor.

The Types segment of the Parkinson's Disease Therapeutics market categorizes the different types of therapeutic treatments available for Parkinson's disease. This segment is vital in understanding the market taxonomy of the Parkinson's Disease Therapeutics market. The types segment is further divided into subtypes, including dopamine agonists, COMT inhibitors, and MAO-B inhibitors. Each subtype has its own set of characteristics and contributes to the overall market size, with dopamine agonists being the most widely used type of treatment.

Parkinson's Disease Therapeutics Segmentation Breakdown10 items

Application

Under 40 Years Old

40-65 Years Old

Above 65 Years Old

Types

Sinemet-CR

Trastal

Madopar

COMT Inhibitor

Other

Regional Insights

Loading chart…

The Parkinson's Disease Therapeutics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market, and Asia Pacific being the fastest-growing region. Key drivers for North America include adoption of advanced therapies, favorable policies, and significant investments in research and development. In Europe, key drivers include a mature ecosystem, high infrastructure development, and a large patient population.

In Asia Pacific, key drivers include a large and growing patient population, increasing demographics awareness, and rising investments in healthcare infrastructure. Latin America and Middle East & Africa are also expected to contribute to the regional forecast, with key drivers including growing adoption of therapeutics, increasing policies support, and improving infrastructure. The Parkinson's Disease Therapeutics market is expected to experience significant growth in the coming years, driven by these regional trends.

Competitive Landscape

The Parkinson's Disease Therapeutics market is moderately consolidated, driven by a mix of global players and local companies. The Parkinson's Disease Therapeutics competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on pricing and distribution.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategic focuses:

Merck: regional expansion

GSK: innovation pipeline

Novartis: premium pricing

Boehringer Ingelheim: local manufacturing

Teva Pharmaceutical: OEM tie-ups

Roche: vertical integration

Key Parkinson's Disease Therapeutics Companies18 items

Merck

Akorn

GSK

Novartis

Boehringer Ingelheim

Teva Pharmaceutical

Abbvie

Kyowa Hakko Kirin Pharma

Astellas Pharma

Roche

H.Lundbeck

Bausch Health

Apokyn

Orion

Stada Arzneimittel

US WorldMeds

Desitin Arzneimittel

Endo Pharmaceuticals

Market Ecosystem

The Parkinson's Disease Therapeutics ecosystem encompasses a complex network of stakeholders, spanning from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main components: upstream, midstream, and downstream. The upstream segment comprises raw material and component suppliers, while the midstream segment involves manufacturers, system integrators, and distributors. The downstream segment consists of channels, service providers, and end users. Value is created and captured as technology providers and suppliers deliver essential components and services to integrators, who then manufacture and distribute therapeutic products to channels and ultimately to end users.

Raw material suppliers — provide active pharmaceutical ingredients

Technology providers — develop novel therapeutic platforms

OEMs/manufacturers — produce Parkinson's disease therapeutic products

Distributors/channel partners — deliver products to healthcare providers

Service providers/after-sales — offer patient support and education services

End users/buyers — patients and healthcare providers

Regulators/standards bodies — oversee therapeutic approvals and compliance

Within the Parkinson's Disease Therapeutics ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approvals and compliance requirements. Dependency risks arise from input constraints, such as limited availability of active pharmaceutical ingredients, and standards, including stringent regulatory approvals. Switching costs are relatively high due to the complex nature of therapeutic products and the need for specialized manufacturing and distribution capabilities. Furthermore, partnerships between technology providers, manufacturers, and distributors are crucial for ensuring seamless product delivery and interoperability. As the ecosystem differs by region, with varying regulatory requirements and market access conditions, a thorough value chain analysis is essential to navigate these complexities and capitalize on emerging opportunities in the Parkinson's Disease Therapeutics ecosystem.

Recent Industry Insights

The Parkinson's Disease Therapeutics industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between pharmaceutical companies and research institutions have accelerated the discovery of novel therapies. Notable mergers and acquisitions have also taken place, enabling companies to expand their product portfolios and strengthen their positions in the market. Furthermore, several product and technology launches have occurred, offering new treatment options for patients.

Additionally, regulatory changes have been implemented to facilitate the approval of innovative treatments, while shifts in consumer and enterprise trends have led to increased focus on personalized medicine and digital health solutions. The industry has also seen significant funding rounds and expansions, with investors backing promising startups and research initiatives. These developments are expected to drive growth and innovation in the Parkinson's Disease Therapeutics market, shaping the future of treatment and care for patients.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Parkinson's Disease Therapeutics market outlook is that it presents a moderately attractive landscape, driven by the increasing prevalence of Parkinson's disease and the growing need for effective treatments. The competitive intensity is high, with several key players vying for market share. In the long term, I anticipate a positive outlook, with ongoing innovation in areas such as gene therapy and immunotherapy expected to drive growth.

The innovation landscape is characterized by a strong focus on personalized medicine and combination therapies. However, the demand-supply balance is a concern, with a shortage of effective treatments for advanced stages of the disease. Key risk factors include regulatory challenges and pricing pressures. Overall, my analysis suggests that the Parkinson's Disease Therapeutics market is poised for growth, but companies must navigate these challenges to capitalize on emerging opportunities.

11 items

1. Executive Summary

2. Parkinson's Disease Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Parkinson's Disease Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Parkinson's Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Under 40 Years Old

6.1.2. 40-65 Years Old

6.1.3. Above 65 Years Old

6.2. Global Parkinson's Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Sinemet-CR

6.2.2. Trastal

6.2.3. Madopar

6.2.4. COMT Inhibitor

6.2.5. Other

6.3. Global Parkinson's Disease Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Parkinson's Disease Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Parkinson's Disease Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Parkinson's Disease Therapeutics Market Competition by Key Manufacturers

8.1. Global Parkinson's Disease Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Parkinson's Disease Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Akorn

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GSK

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Boehringer Ingelheim

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Teva Pharmaceutical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbvie

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Kyowa Hakko Kirin Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Astellas Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Roche

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. H.Lundbeck

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bausch Health

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Apokyn

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Orion

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Stada Arzneimittel

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. US WorldMeds

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Desitin Arzneimittel

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Endo Pharmaceuticals

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Parkinson's Disease Therapeutics Market

Figure 4: Global Parkinson's Disease Therapeutics Market: Drivers

Figure 5: Global Parkinson's Disease Therapeutics Market: Challenges

Figure 6: Global Parkinson's Disease Therapeutics Market: Trends

Figure 7: Global Parkinson's Disease Therapeutics Market: Opportunity

Figure 8: Global Parkinson's Disease Therapeutics Market: Restraint

Figure 9: Global Parkinson's Disease Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Parkinson's Disease Therapeutics Market Value (USD Million) By Region

Figure 15: Global Parkinson's Disease Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Parkinson's Disease Therapeutics Market Value (USD Million) By Region

Figure 23: Global Parkinson's Disease Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Parkinson's Disease Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Parkinson's Disease Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Parkinson's Disease Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Parkinson's Disease Therapeutics Market Value (USD Million) By Region

Table 10: Global Parkinson's Disease Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Parkinson's Disease Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Parkinson's Disease Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Parkinson's Disease Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Akorn Basic Information And Sales Area

Table 33: Akorn. Products Portfolio

Table 34: GSK Basic Information And Sales Area

Table 35: GSK. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Boehringer Ingelheim Basic Information And Sales Area

Table 39: Boehringer Ingelheim. Products Portfolio

Table 40: Teva Pharmaceutical Basic Information And Sales Area

Table 41: Teva Pharmaceutical. Products Portfolio

Table 42: Abbvie Basic Information And Sales Area

Table 43: Abbvie. Products Portfolio

Table 44: Kyowa Hakko Kirin Pharma Basic Information And Sales Area

Table 45: Kyowa Hakko Kirin Pharma. Products Portfolio

Table 46: Astellas Pharma Basic Information And Sales Area

Table 47: Astellas Pharma. Products Portfolio

Table 48: Roche Basic Information And Sales Area

Table 49: Roche. Products Portfolio

Table 50: H.Lundbeck Basic Information And Sales Area

Table 51: H.Lundbeck. Products Portfolio

Table 52: Bausch Health Basic Information And Sales Area

Table 53: Bausch Health. Products Portfolio

Table 54: Apokyn Basic Information And Sales Area

Table 55: Apokyn. Products Portfolio

Table 56: Orion Basic Information And Sales Area

Table 57: Orion. Products Portfolio

Table 58: Stada Arzneimittel Basic Information And Sales Area

Table 59: Stada Arzneimittel. Products Portfolio

Table 60: US WorldMeds Basic Information And Sales Area

Table 61: US WorldMeds. Products Portfolio

Table 62: Desitin Arzneimittel Basic Information And Sales Area

Table 63: Desitin Arzneimittel. Products Portfolio

Table 64: Endo Pharmaceuticals Basic Information And Sales Area

Table 65: Endo Pharmaceuticals. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Parkinson's Disease Therapeutics Market Value (USD Million) By Region

Table 71: Global Parkinson's Disease Therapeutics Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Parkinson's Disease Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Akorn; GSK; Novartis; Boehringer Ingelheim; Teva Pharmaceutical; Abbvie; Kyowa Hakko Kirin Pharma; Astellas Pharma; Roche; H.Lundbeck; Bausch Health; Apokyn; Orion; Stada Arzneimittel; US WorldMeds; Desitin Arzneimittel; Endo Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in neuroprotection and gene therapy are driving innovation in the Parkinson's Disease Therapeutics market, offering new avenues for treatment and management of the condition.

Restraints2 items

The high cost of research and development in the Parkinson's Disease Therapeutics market, coupled with the risk of failed trials, is a significant restraint to market growth.

Stringent regulatory requirements and the need for extensive clinical trials are barriers to entry for new players in the Parkinson's Disease Therapeutics market, limiting the pace of innovation.

Opportunities2 items

Challenges2 items

The complexity of Parkinson's disease and the lack of a cure pose significant challenges to the development of effective therapeutics, requiring ongoing investment in research and development.

Market Segmentation

Loading chart…

Parkinson's Disease Therapeutics Segmentation Breakdown10 items

Application

Under 40 Years Old

40-65 Years Old

Above 65 Years Old

Types

Sinemet-CR

Trastal

Madopar

COMT Inhibitor

Other

Regional Insights

Loading chart…

Competitive Landscape

Merck: regional expansion

GSK: innovation pipeline

Novartis: premium pricing

Boehringer Ingelheim: local manufacturing

Teva Pharmaceutical: OEM tie-ups

Roche: vertical integration

Key Parkinson's Disease Therapeutics Companies18 items

Merck

Akorn

GSK

Novartis

Boehringer Ingelheim

Teva Pharmaceutical

Abbvie

Kyowa Hakko Kirin Pharma

Astellas Pharma

Roche

H.Lundbeck

Bausch Health

Apokyn

Orion

Stada Arzneimittel

US WorldMeds

Desitin Arzneimittel

Endo Pharmaceuticals

Market Ecosystem

Raw material suppliers — provide active pharmaceutical ingredients

Technology providers — develop novel therapeutic platforms

OEMs/manufacturers — produce Parkinson's disease therapeutic products

Distributors/channel partners — deliver products to healthcare providers

Service providers/after-sales — offer patient support and education services

End users/buyers — patients and healthcare providers

Regulators/standards bodies — oversee therapeutic approvals and compliance

Recent Industry Insights

Analyst Overview

Table of Contents